Skip to content

How a Biopharma Plant Reduced Cross-Contamination Using Single-Use Assemblies

As biologics pipelines expand and batch sizes become more varied, contamination control has become central to both compliance and competitiveness. For multi-product biopharma facilities, traditional stainless-steel systems can introduce operational risk and slow down campaign changeovers. 

This use case outlines how one biologics manufacturer reduced cross-contamination risk and improved operational efficiency by integrating custom single-use assemblies into its process design. 

The facility produced monoclonal antibodies and recombinant proteins across clinical and commercial supply. Each product changeover required:
• Cleaning-in-place and sterilisation-in-place cycles
• Surface sampling and analytical verification
• Extended equipment downtime

Whilst fully compliant, the process was resource-intensive and constrained manufacturing flexibility. As production schedules tightened and molecule diversity increased, the risk profile of shared product-contact surfaces became a growing concern. 

Leadership identified a clear objective: reduce contamination risk without expanding infrastructure or compromising throughput. 

The plant transitioned from critical fluid handling steps to bespoke single-use assemblies, manufactured within a controlled cleanroom environment. 

The solution included:
• Gamma-irradiated tubing and bag assemblies for upstream and downstream workflows
• Closed transfer systems for media, buffers and product harvest 
• Custom manifolds designed to simplify fluid routing and minimise manual intervention 

Each assembly was engineered to integrate with existing bioreactors, filtration systems and filling lines, removing reusable contact surfaces from high-risk stages of the process. 

The approach shifted contamination control from reactive cleaning to preventative design. 

1. Lower Cross-Contamination Exposure
By eliminating shared flow paths between campaigns, the facility significantly reduced the likelihood of product carry-over. Quality teams reported increased confidence during product transitions and simplified documentation during audits.

2. Faster Turnaround Between Batches 
Replacing assemblies proved substantially quicker than executing full cleaning and validation cycles. Downtime between campaigns was reduced, improving overall equipment effectiveness.

3. Reduced Cleaning Burden
Lower demand for water-for-injection, cleaning chemicals and revalidation cycles delivered measurable cost and resource efficiencies.

4. Future-Proofed Operations
Although focused on biologics, the shift to closed, sterile single-use systems also strengthened the facility’s readiness for next-generation modalities, should pipeline strategy evolve.

For multi-product biologics facilities, contamination risk increases as portfolios diversify. Managing that risk solely through cleaning validation places pressure on time, utilities and quality teams. 

This case demonstrates that contamination control can be addressed structurally, through process redesign using single-use assemblies tailored to specific applications. 

The value lies not simply in disposability, but in:
• Custom engineering aligned with process parameters
• Regulatory-compliant cleanroom manufacturing
• Reliable supply continuity
• Technical collaboration throughout design and implementation

As biologics manufacturing becomes more complex and competitive, facilities that embed contamination control into process architecture will be better positioned to scale efficiently and operate with confidence. 

BioPharma Dynamics supports this transition through tailored single-use solutions designed for performance, compliance, and long-term manufacturing resilience.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Pin It on Pinterest